Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anti-α5β8 integrin antibody
- Development stage
- Preclinical
- Lead developer
- Northwestern University
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Anti-α5β8 integrin antibody is a monoclonal antibody designed to target and inhibit the α5β8 integrin complex. In the context of glioblastoma (GBM) research, this integrin has been identified as a critical component in the activation and release of Transforming Growth Factor-beta (TGFβ) within the tumor microenvironment. By blocking α5β8, the antibody prevents the immunosuppressive effects of TGFβ, thereby promoting the accumulation of germinal-center-like B cells and enhancing the anti-tumor activity of T cells. Preclinical studies in murine glioma models have shown that treatment with an anti-α5β8 antibody, particularly in combination with PD-1 blockade, can increase the infiltration of proliferating B-cells and significantly extend survival. This approach highlights a potential therapeutic strategy for modulating the immune landscape of 'cold' tumors like glioblastoma.
- Other names
- anti-a5b8 integrin antibodyanti-a-5b8 integrin antibodyanti-a 5b8 integrin antibody
02
Targets
αVβ8 (Integrin alpha V beta 8)
Beyond the preview
Go deeper on anti-α5β8 integrin antibody.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anti-α5β8 integrin antibody.